psychiatryRounds

Connecting Psychiatry - Expert community for all mental health professionals

(PSYCHIATRIC TIMES) - Nycomed and Neurochem have struck an alliance aimed at developing novel technologies for the diagnosis of Alzheimer’s disease. Using Neurochem’s proprietary molecules as a basis, the two companies will work on the design and selection of a product to detect the presence of amyloid plaques that accumulate in the brains of Alzheimer’s patients.

For full article, please visit:
http://www.psychiatrictimes.com/alzheimer-dementia/article/113619/1...

Views: 7

Comment

You need to be a member of psychiatryRounds to add comments!

Join psychiatryRounds


psychiatryRounds Social Media

Sponsors

CMEinfo: Board Reviews in Anesthesia, Cardiology, Internal Medicine, Radiology

© 2019   Created by PsychiatryRounds Team.   Powered by

Badges  |  Report an Issue  |  Terms of Service